Collegium Pharmaceutical, Inc. (COLL) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 4:05 PM EDT
Company Participants
Vikram Karnani – CEO, President & Director
Colleen Tupper – Executive VP & CFO
Conference Call Participants
Robert Klingenberger
Presentation
Robert Klingenberger
Thank you. Thank you. Great. Good afternoon. My name is Bob Klingenberger. I’m an Executive Director at Morgan Stanley. I’m really pleased to be joined by the Collegium team here this afternoon. Vikram Karnani, President and Chief Executive Officer, and Colleen Tupper, CFO. And just before we get started for any research disclaimers, please just visit morganstanley.com/researchdisclosure. And if any questions, please reach out to your Morgan Stanley representative. And like I said, thrilled to be joined here by the Collegium team.
Question-and-Answer Session
Robert Klingenberger
And I think Vikram and Colleen, just maybe to, kind of, kick things off, historically I think the company has been viewed as a really a pain management company. I think fair to say that the story today is increasingly diversified and just maybe to kick us off would be great if you could, kind of, describe the transformation and how you guys, especially Vikram, since you’ve been in the seat, have really, kind of, transformed the profile the last couple of years.
Vikram Karnani
CEO, President & Director
Yes, first of all, thank you. Thanks for having us. To give you a little bit of background on Collegium, we describe ourselves as a dynamic, growing biopharmaceutical company, focusing on improving the lives of people living with serious and often misunderstood conditions. There are three main components to how we do what we do. We identify differentiated commercial assets or medicines that address meaningful unmet needs for patients. We apply focused commercial execution strategies and efforts to accelerate growth. And then finally, we create value through strategic acquisition and business development.
